Covariates which were statistically significant in univariate evaluation or considered relevant were contained in the multivariate evaluation clinically
July 29, 2022
Covariates which were statistically significant in univariate evaluation or considered relevant were contained in the multivariate evaluation clinically. Results 3 hundred and nine patients completed the principal group of three doses of hepatitis B vaccine through the study period. 6 to a year after completing major vaccine series to be able to identify early supplementary vaccine failure. PDE12-IN-3 ideals 0.05 were considered significant. Covariates which were statistically significant in univariate evaluation or considered relevant were contained in the multivariate evaluation clinically. Results 3 hundred and nine individuals completed the principal group of three dosages of hepatitis B vaccine through the research period. Post-vaccination HBsAb tests after the third dose were available for 178 patients; these constitute the study population. Tables 1 and ?and22 show baseline characteristics of the study population and univariate predictors of serologic response. Overall, 42% (75/178; 95% confidence interval (CI): 35C49%) developed HBsAb after receiving three doses. In univariate analysis, CD4 cell counts 350 cells/mm3 (30% versus 50%, = 0.015) and AIDS (48% versus 66%, = 0.017) at time of the first vaccine dose were associated with a lack of HBsAb at the time of testing. Eleven percent (20/178) had HBsAb test within 60 days of the third dose, 21% (37/178) were tested between 60 and 179 days, 21% (37/178) between 180 and 359 days and 47% (84/178) at 360 days. Times between the third vaccine dose and the first post-vaccine HBsAb testing were categorized and examined with using the following tabulated time cutoff points: 59 days, 60C89 days, 90C119 days, 120C179 days, 180C359 days and 360 days. The likelihood of seroconversion was inversely related to time to testing vaccine responses (= 0.009). Table 1 Baseline characteristics and univariate predictors of serologic response. ValueValue= 0.049) and at 360 days (OR = 0.065 [95% CI: 0.007C0.636], = 0.019) after the third dose. AIDS (either nadir CD4 cell count 200 cells/mm3 or history of AIDS defining illness or both) at time of the first vaccine dose was also independently associated with lower HBsAb seropositivity rates (OR = 0.367 [95% CI: 0.155C0.867], = 0.022). Table 3 Multivariate predictors for serologic response. PDE12-IN-3 Value /th th align=”left” valign=”top” rowspan=”1″ colspan=”1″ OR (95% CI) /th /thead Age groupb????10.4391.601 (0.486C5.271)????20.5680.684 (0.185C2.527)????30.6751.277 (0.406C4.016)????40.3621.715 (0.537C5.471)Gender????Malereference????Female0.8381.080 (0.517C2.256)Smoking????Neverreference????Current0.3070.472 (0.112C1.988)????Ever0.2490.613 (0.267C1.409)HCV VL detectable0.7820.883 (0.369C2.115)AIDS0.022a0.367 (0.155C0.867)CD4 at 1st dose 3500.3431.513 (0.643C3.563)Days to post vaccine HBsAb test????59reference????60C890.6370.531 (0.038C7.378)????90C1190.0670.091 PDE12-IN-3 (0.007C1.178)????120C1790.1790.167 (0.012C2.269)????180C3590.049a0.077 (0.006C0.993)????3600.019a0.065 (0.007C0.636) Open in a separate window aStatistically significant. bThe study population was equally divided into five age groups. The oldest age group was used as a reference. Discussion We found that rates of HBsAb seropositivity were significantly decreased among those tested 180 days after the third PDE12-IN-3 vaccine dose. Rabbit Polyclonal to ZNF225 The significant decrease in seropositivity rates over time is suggestive of a rapid loss of vaccine-acquired immunity in primary responders. Prior studies demonstrated the loss of vaccine-acquired HBsAb in small numbers of HIV-infected patients, even in those with CD4 cell counts 200 cells/mm3, and with a variety of vaccine dosing regimens.9,16,17 For example, Rey et al.9 reported the follow-up serologic testing for vaccine responders in a rapid vaccine PDE12-IN-3 schedule. In their study, 20 patients received 20 mcg of recombinant hepatitis B vaccine at 0, 1, 2 months. The number of initial responders were 11 (55%) and seven more patients responded to additional three booster doses, which improved overall response rate to 90%. However, 12 months after the first vaccine dose (10 months after the last vaccine dose) only 58.8% (10/17) of those patients had positive HBsAb. All of those patients had CD4 cell counts 200 cells/mm3 and median CD4 cell counts and median nadir CD4 cell counts were 470 cells/mm3 and 286 cells/mm3, respectively. Cruciani et al.17 vaccinated HIV-infected persons using high dose (40 mcg) hepatitis B vaccine given at 0, 1, 2 months. In their study, 65 patients completed the vaccine schedule and 39 (60%) patients had primary.